Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer with limited treatment options for relapsed/refractory cases.
• Targeting T-ALL is difficult due to shared antigens between leukemic and normal T cells.
• Leukemia-initiating cells (LICs) drive T-ALL progression and are key therapeutic targets.

Purpose of the Study:

• To identify novel biomarkers for T-ALL LICs.
• To evaluate the pre-T cell receptor (pre-TCR) as a therapeutic target for T-ALL.
• To develop and validate targeted immunotherapies against pre-TCR in T-ALL.

Main Methods:

• Identification of pre-TCR as a T-ALL LIC biomarker in human samples.
• Loss-of-function genetic studies in mouse xenografts to assess pre-TCR signaling necessity.
• Development and in vivo validation of anti-pTα monoclonal antibody and antibody-drug conjugate therapies.

Main Results:

• Pre-TCR is a specific biomarker for T-ALL LICs.
• Pre-TCR signaling is essential for T-ALL LIC activity and tumor progression.
• Anti-pTα antibody-drug conjugate therapy effectively inhibits LICs and T-ALL progression in vivo.

Conclusions:

• The pre-T cell receptor is a viable and specific therapeutic target for T-ALL.
• Targeting pre-TCR with antibody-drug conjugates shows promise as a potent immunotherapy for T-ALL.
• This strategy offers a potential new treatment for relapsed/refractory T-ALL patients expressing pre-TCR.